Related Experiment Videos
Clinical trials of antiangiogenic agents
1Robert H. Lurie Cancer Center, Northwestern University Medical School, Division of Hematology/Oncology, Chicago, IL 60611, USA.
Abstract:
Acquisition of new blood vessels is a required step in malignant transformation, tumor growth, and metastasis. Inhibition of angiogenesis is one of the most promising new strategies for the treatment of malignant neoplasms. In recent years, several antiangiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have entered clinical trials. In this we review, we look at the results of early clinical trials of these agents and discuss the new angiogenesis inhibitors in preclinical development.
Insights
Inhibiting new blood vessel growth (angiogenesis) is key to stopping cancer growth and spread. Early clinical trials show promise for new anti-angiogenic drugs in cancer treatment.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor development, growth, and metastasis.
- Inhibiting angiogenesis presents a promising therapeutic strategy for treating malignant neoplasms.
Purpose of the Study:
- To review the outcomes of early clinical trials involving anti-angiogenic compounds.
- To discuss novel angiogenesis inhibitors currently in preclinical development.
Main Methods:
- Review of early-phase clinical trial data for anti-angiogenic agents.
- Analysis of preclinical data for emerging angiogenesis inhibitors.
Main Results:
- Several anti-angiogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and tecogalan sodium, have advanced to clinical trials.
- Early clinical trial results for these agents are presented and discussed.
Conclusions:
- Anti-angiogenesis therapy is a significant area of research in cancer treatment.
- Ongoing development of new angiogenesis inhibitors shows potential for future cancer therapies.